Is STTK or SION more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Sionna Therapeutics N/A -27.31% -25.88%

Do analysts rate STTK or MESO?

Shattuck Labs presently has a consensus price target of $12.63, indicating a potential upside of 78.57%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is STTK or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Mesoblast N/A N/A N/A

Is STTK or PVLA more profitable?

Palvella Therapeutics' return on equity of -56.87% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Palvella Therapeutics N/A -56.87% -42.50%

Shattuck Labs (STTK) Competitors

$7.07 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$7.20 +0.13 (+1.78%)

As of 07/31/2026 07:35 PM Eastern

Compare

STTK vs. URGN, HRMY, SION, MESO, and PVLA

Should you buy Shattuck Labs stock or one of its competitors? MarketBeat compares Shattuck Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shattuck Labs include Urogen Pharma (URGN), Harmony Biosciences (HRMY), Sionna Therapeutics (SION), Mesoblast (MESO), and Palvella Therapeutics (PVLA).

How does Shattuck Labs compare to Urogen Pharma?

Shattuck Labs (NASDAQ:STTK) and Urogen Pharma (NASDAQ:URGN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Shattuck Labs has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

Shattuck Labs has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	542.13	-$48.81M	-$0.63	N/A
Urogen Pharma	$109.79M	16.97	-$153.49M	-$2.75	N/A

In the previous week, Urogen Pharma had 9 more articles in the media than Shattuck Labs. MarketBeat recorded 9 mentions for Urogen Pharma and 0 mentions for Shattuck Labs. Urogen Pharma's average media sentiment score of 0.97 beat Shattuck Labs' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Urogen Pharma	Positive

Shattuck Labs currently has a consensus price target of $12.63, indicating a potential upside of 78.57%. Urogen Pharma has a consensus price target of $41.63, indicating a potential upside of 8.85%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Shattuck Labs has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Urogen Pharma	-94.83%	N/A	-62.85%

Summary

Shattuck Labs beats Urogen Pharma on 10 of the 17 factors compared between the two stocks.

How does Shattuck Labs compare to Harmony Biosciences?

Shattuck Labs (NASDAQ:STTK) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Shattuck Labs currently has a consensus price target of $12.63, suggesting a potential upside of 78.57%. Harmony Biosciences has a consensus price target of $42.63, suggesting a potential upside of 20.96%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities research analysts plainly believe Shattuck Labs is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Harmony Biosciences had 10 more articles in the media than Shattuck Labs. MarketBeat recorded 10 mentions for Harmony Biosciences and 0 mentions for Shattuck Labs. Harmony Biosciences' average media sentiment score of 1.17 beat Shattuck Labs' score of 0.00 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Harmony Biosciences	Positive

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Shattuck Labs has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Harmony Biosciences has a net margin of 16.20% compared to Shattuck Labs' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Harmony Biosciences	16.20%	17.19%	11.99%

Harmony Biosciences has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	542.13	-$48.81M	-$0.63	N/A
Harmony Biosciences	$899.11M	2.27	$158.69M	$2.48	14.21

Summary

Harmony Biosciences beats Shattuck Labs on 12 of the 17 factors compared between the two stocks.

How does Shattuck Labs compare to Sionna Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Sionna Therapeutics (NASDAQ:SION) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Sionna Therapeutics' return on equity of -27.31% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Sionna Therapeutics	N/A	-27.31%	-25.88%

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Sionna Therapeutics had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 3 mentions for Sionna Therapeutics and 0 mentions for Shattuck Labs. Sionna Therapeutics' average media sentiment score of 1.22 beat Shattuck Labs' score of 0.00 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Sionna Therapeutics	Positive

Shattuck Labs presently has a consensus target price of $12.63, indicating a potential upside of 78.57%. Sionna Therapeutics has a consensus target price of $53.22, indicating a potential upside of 12.93%. Given Shattuck Labs' higher probable upside, equities analysts clearly believe Shattuck Labs is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Shattuck Labs has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	542.13	-$48.81M	-$0.63	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Shattuck Labs has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Summary

Shattuck Labs beats Sionna Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Mesoblast?

Shattuck Labs (NASDAQ:STTK) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Shattuck Labs has higher earnings, but lower revenue than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	542.13	-$48.81M	-$0.63	N/A
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A

Mesoblast's return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Mesoblast	N/A	N/A	N/A

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Mesoblast had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 3 mentions for Mesoblast and 0 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.00 equaled Mesoblast'saverage media sentiment score.

Company	Overall Sentiment
Shattuck Labs	Neutral
Mesoblast	Neutral

Shattuck Labs presently has a consensus price target of $12.63, indicating a potential upside of 78.57%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Shattuck Labs has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Summary

Mesoblast beats Shattuck Labs on 8 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Palvella Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Shattuck Labs has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Palvella Therapeutics' return on equity of -56.87% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Palvella Therapeutics	N/A	-56.87%	-42.50%

In the previous week, Palvella Therapeutics had 9 more articles in the media than Shattuck Labs. MarketBeat recorded 9 mentions for Palvella Therapeutics and 0 mentions for Shattuck Labs. Palvella Therapeutics' average media sentiment score of 1.03 beat Shattuck Labs' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Palvella Therapeutics	Positive

Shattuck Labs presently has a consensus price target of $12.63, suggesting a potential upside of 78.57%. Palvella Therapeutics has a consensus price target of $199.53, suggesting a potential upside of 43.51%. Given Shattuck Labs' higher possible upside, equities research analysts plainly believe Shattuck Labs is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palvella Therapeutics has higher revenue and earnings than Shattuck Labs. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	542.13	-$48.81M	-$0.63	N/A
Palvella Therapeutics	$42.81M	46.57	-$41.72M	-$4.17	N/A

Summary

Palvella Therapeutics beats Shattuck Labs on 10 of the 16 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$542.14M	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-11.22	7.38	282.28	24.66
Price / Sales	542.13	1,199.83	563.21	75.35
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	5.44	16.96	10.96	6.07
Net Income	-$48.81M	-$12.56M	$3.49B	$347.99M
7 Day Performance	0.43%	-1.80%	-0.63%	-0.44%
1 Month Performance	0.28%	-8.44%	-5.23%	-4.81%
1 Year Performance	865.85%	48.63%	62.07%	18.61%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	2.3136 of 5 stars	$7.07 flat	$12.63 +78.6%	+865.8%	$542.14M	$1M	N/A	100	Gap Up
URGN Urogen Pharma	2.8185 of 5 stars	$43.78 +6.5%	$41.63 -4.9%	+97.1%	$2.13B	$140.49M	N/A	200	Upcoming Earnings Gap Up
HRMY Harmony Biosciences	4.6579 of 5 stars	$36.84 +10.0%	$42.50 +15.4%	+2.4%	$2.13B	$868.45M	14.85	200	Upcoming Earnings Analyst Forecast High Trading Volume
SION Sionna Therapeutics	2.1718 of 5 stars	$47.21 +3.3%	$53.22 +12.7%	+178.5%	$2.13B	N/A	N/A	35	Positive News
MESO Mesoblast	0.3351 of 5 stars	$16.42 -1.3%	N/A	-6.6%	$2.13B	$65.38M	N/A	80	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. URGN, HRMY, SION, MESO, and PVLA

How does Shattuck Labs compare to Urogen Pharma?

Summary

How does Shattuck Labs compare to Harmony Biosciences?

Summary

How does Shattuck Labs compare to Sionna Therapeutics?

Summary

How does Shattuck Labs compare to Mesoblast?

Summary

How does Shattuck Labs compare to Palvella Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. URGN, HRMY, SION, MESO, and PVLA

How does Shattuck Labs compare to Urogen Pharma?

Which has more risk and volatility, STTK or URGN?

Which has higher valuation & earnings, STTK or URGN?

Does the media favor STTK or URGN?

Do analysts prefer STTK or URGN?

Do institutionals and insiders believe in STTK or URGN?

Is STTK or URGN more profitable?

Summary

How does Shattuck Labs compare to Harmony Biosciences?

Do analysts prefer STTK or HRMY?

Does the media refer more to STTK or HRMY?

Do insiders & institutionals have more ownership in STTK or HRMY?

Which has more risk & volatility, STTK or HRMY?

Is STTK or HRMY more profitable?

Which has preferable valuation & earnings, STTK or HRMY?

Summary

How does Shattuck Labs compare to Sionna Therapeutics?

Is STTK or SION more profitable?

Do institutionals and insiders have more ownership in STTK or SION?

Does the media favor STTK or SION?

Do analysts recommend STTK or SION?

Which has stronger earnings & valuation, STTK or SION?

Which has more risk & volatility, STTK or SION?

Summary

How does Shattuck Labs compare to Mesoblast?

Which has stronger valuation and earnings, STTK or MESO?

Is STTK or MESO more profitable?

Do institutionals & insiders have more ownership in STTK or MESO?

Does the media favor STTK or MESO?

Do analysts rate STTK or MESO?

Which has more volatility and risk, STTK or MESO?

Summary

How does Shattuck Labs compare to Palvella Therapeutics?

Which has more risk & volatility, STTK or PVLA?

Do insiders and institutionals hold more shares of STTK or PVLA?

Is STTK or PVLA more profitable?

Does the media prefer STTK or PVLA?

Do analysts recommend STTK or PVLA?

Which has better earnings & valuation, STTK or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools